demonstrated that prolonged, long-term, moderate hypoxia can promote resistance to the third-generation EGFR-TKI osimertinib (AZD9291) in the NSCLC cell line H1975 that had developed resistance to first- and second-generation EGFR-TKIs via the T790M EGFR mutation (43, 48). This evidence concerns the gene EGFR and non-small cell lung carcinoma.